Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.

Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, DeFronzo RA.

Diabetes. 2014 Aug;63(8):2812-20. doi: 10.2337/db13-1130.

2.
3.

Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.

Liang H, Tantiwong P, Sriwijitkamol A, Shanmugasundaram K, Mohan S, Espinoza S, Defronzo RA, Dubé JJ, Musi N.

J Physiol. 2013 Jun 1;591(11):2897-909. doi: 10.1113/jphysiol.2012.247510.

4.

Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.

Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.

Diabetes. 2005 Nov;54(11):3148-53.

5.
6.

Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans.

Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, DeFronzo RA, Tripathy D.

Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E758-64. doi: 10.1152/ajpendo.90737.2008.

7.

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA.

Gastroenterology. 2007 Aug;133(2):496-506.

PMID:
17681171
8.

Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.

Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.

J Clin Endocrinol Metab. 2016 Mar;101(3):1249-56. doi: 10.1210/jc.2015-2597.

PMID:
26765576
9.

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.

Diabetes. 1999 Sep;48(9):1836-41.

PMID:
10480616
10.

Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.

Makimura H, Stanley TL, Suresh C, De Sousa-Coelho AL, Frontera WR, Syu S, Braun LR, Looby SE, Feldpausch MN, Torriani M, Lee H, Patti ME, Grinspoon SK.

J Clin Endocrinol Metab. 2016 Mar;101(3):1123-33. doi: 10.1210/jc.2015-3696.

PMID:
26691888
11.
13.

Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin.

Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA.

Acta Diabetol. 2008 Sep;45(3):147-50. doi: 10.1007/s00592-008-0033-z.

PMID:
18357404
14.

Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.

Lim EL, Hollingsworth KG, Smith FE, Thelwall PE, Taylor R.

Clin Sci (Lond). 2011 Aug;121(4):169-77. doi: 10.1042/CS20100611.

15.

Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.

Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.

J Clin Endocrinol Metab. 1998 Dec;83(12):4350-4.

PMID:
9851776
16.

Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients.

Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA.

Int J Obes Relat Metab Disord. 2003 Jan;27(1):88-94.

PMID:
12532159
17.

Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D.

Diabetes Care. 2009 Aug;32(8):1542-6. doi: 10.2337/dc09-0684.

18.

Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.

Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, Mandarino L, Kashyap S, Belfort R, DeFronzo RA.

Am J Physiol Endocrinol Metab. 2002 Jun;282(6):E1360-8.

19.

Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.

Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.

J Clin Endocrinol Metab. 2001 Dec;86(12):5813-8.

PMID:
11739444
20.

The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus.

Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA.

J Clin Endocrinol Metab. 1991 Jan;72(1):96-107.

PMID:
1986032
Items per page

Supplemental Content

Support Center